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Abstract
Background: Cancer patients receiving chemotherapy are at increased risk of thrombosis. Nadroparin has been
demonstrated to reduce the incidence of venous and arterial thrombotic events (TEs) by about 50% in cancer
outpatients receiving chemotherapy. The aims of this retrospective analysis were to evaluate the thromboembolic
risk and the benefit of thromboprophylaxis according to type of chemotherapy.
Methods: Cancer outpatients were randomly assigned to receive subcutaneous injections of nadroparin or
placebo. The incidence of symptomatic TEs was assessed according to the type of chemotherapy. Results were
reported as risk ratios with associated 95% CI and two-tailed probability values.
Results: 769 and 381 patients have been evaluated in the nadroparin and placebo group, respectively. In the
absence of thromboprophylaxis, the highest rate of TEs was found in patients receiving gemcitabine- (8.1%) or
cisplatin-based chemotherapy (7.0%). The combination of gemcitabine and cisplatin or carboplatin increased the
risk to 10.2%. Thromboprophylaxis reduced TE risk by 68% in patients receiving gemcitabine; with a further
decrease to 78% in those receiving a combination of gemcitabine and platinum.
Conclusions: This retrospective analysis confirms that patients undergoing chemotherapy including gemcitabine,
platinum analogues or their combination are at higher risk of TEs. Our results also suggest that outpatients
receiving chemotherapy regimens including these agents might achieve an increased benefit from
thromboprophylaxis with nadroparin. Clinical Trial registration number: NCT 00951574
Keywords: chemotherapy, nadroparin, prophylaxis, thrombosis, LMWH
Background
Cancer patients are at increased risk of thrombosis [1].
Thromboembolic complications may be the first mani-
festation of malignancy and are associated with a high
rate of morbidity and mortality [2]. Thromboembolic
events (TEs) occur in 4-20% of patients with cancer [3].
Evidences of thrombosis have been reported in up to
50% of cancer patients in autoptic series [4]. TEs and
infections are the second cause of death in cancer
patients after the cancer itself [5].
Large studies have suggested that some solid malig-
nancies including pancreatic, lung, colon, ovarian, pri-
mary hepatic and brain cancer are associated with a
higher risk of TEs [6,7]. Risk factors, such as age, gen-
der, bed-rest, venous catheters, surgery, radiotherapy
and infections, also increase the risk of thrombosis in
cancer patients [8].
Epidemiological studies have identified chemotherapy
as an additional risk factor for a hypercoagulability state
and thrombosis [9]. The pathophysiology of chemother-
apy-related TEs may involve a variety of mechanisms
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anticoagulant synthesis, stimulation of platelet aggrega-
tion and endothelial damage [10]. In a population-based
study, chemotherapy was associated with risk of venous
TEs that was increased 6.5-fold compared to non-cancer
patients [11]. Platinum analogues, anthracyclines and
fluoropyrimidines are agents mostly associated with a
pro-thrombotic effect. In a prospective study, platinum-
based regimens were significantly associated with venous
TEs [12]. Even within this class of agents, rates of TEs
seem to be higher in patients receiving cisplatin com-
pared to oxaliplatin [13]. Gemcitabine has also been
associated with remarkable thrombotic and vascular side
effects [14]. Lastly, venous thromboembolic disease and
catheter-related thrombosis have been documented in
patients receiving 5-fluorouracil [15-18]. The use of con-
comitant steroids, erythropoietin preparations and gran-
ulocyte colony-stimulating factors (G-CSF) has also
been associated with an increased incidence of TEs in
cancer patients [9].
Recently, Agnelli et al [19] demonstrated that nadro-
parin almost halved, from 3.9% to 2.0%, the absolute
rate of thromboembolic complications. The overall
amount of reduction in symptomatic outcomes is con-
sistent with those attributable to low-molecular-weight
h e p a r i ni np r e v e n t i o no fv e n o u st h r o m b o e m b o l i s mi n
other clinical settings [20].
The PROTECHT (PROphylaxis of ThromboEmbolism
during CHemoTherapy) study highlighted chemotherapy
as an independent risk factor for thromboembolism in a
wide cancer population and defined the benefit of
thromboprophylaxis [21]. The PROTECHT results have
not the impact to change current practice for TE pro-
phylaxis in the overall ambulatory cancer population
receiving chemotherapy, otherwise a selection of
patients The aims of this retrospective analysis were to
identify subgroups of patients at high risk of TEs, strati-
fied according to the type of chemotherapy, who could
have an enhanced benefit from TEs prophylaxis.
Patients and methods
Design of the PROTECHT Study
The PROTECHT (PROphylaxis of ThromboEmbolism
during CHemoTherapy) was a randomized, group
sequential, placebo-controlled, double-blind, multicentre,
clinical outcome study (NCT 00951574) [19]. Outpatients
with metastatic or locally advanced solid tumours were
randomized in a 2:1 ratio to receive either subcutaneous
injections of nadroparin (3800 anti-Xa IU once daily) or
placebo. Study treatment was started on the same day as
chemotherapy and was given for the duration of che-
motherapy or up to a maximum of 120 days (+/- 10
days). The primary outcome was the composite endpoint
of symptomatic venous or arterial thromboembolic
events, as adjudicated by an independent committee.
Major bleeding was the main safety outcome.
Retrospective analysis of the PROTECHT study popu-
lation, according to type of chemotherapy and concomi-
tant medications, was carried out. All cytotoxic agents
used in ≥ 1% of patients were evaluated. All concomi-
tant medications that might potentially interact with
coagulation factors were evaluated: steroids, G-CSF,
nonsteroidal anti-inflammatory drugs, aspirin, erythro-
poietin, blood and related products [9].
An evaluation of the TE risk according to Khorana
score [22] has been evaluated. This predictive score
assigns 2 points to very high risk cancer sites (pancreatic
or gastric) or 1 point to high risk cancer sites (lung,
ovarian or bladder). In addition, 1 point is assigned for
each of the followings: platelet count > 350 × 109/L,
hemoglobin < 10 g/dl and/or use of erythropoietin-sti-
mulating agents, leukocyte count > 11 × 109/L and
body mass index > 35 kg/m2. Patients with a score ≥ 3
are at high risk to develop TEs
The study was done in accordance with the provisions
of the Declaration of Helsinki and local regulations. The
protocol was approved by the institutional review board
at each study centre, and written inform consent was
obtained from all patients before randomization.
Statistical Methods
Descriptive statistics refer to all included patients. For
continuous variables, the mean, standard deviation,
median, minimum and maximum values were calcu-
lated. For each discrete variable, the number of cases in
each category, in relation to all cases with non-missing
values of that variable, was calculated.
Venous and arterial TE rates, grouped by the type of
chemotherapy regimen, were reported as risk ratios
(RRs) with associated two-tailed 95% CI. The approach
adopted for the sub-group analyses consisted in consid-
ering findings as hypothesis-generating as a guide to
prioritize additional studies. Hence, no adjustment of
type I error rate was adopted for the multiplicity of con-
fidence intervals over sub-groups. All statistical calcula-
tions were carried out using SAS version 9.1.
Results
Overall, 1150 patients were included in the primary effi-
cacy and safety analyses of the PROTECHT study. Fif-
teen of the 769 patients treated with nadroparin (2.0%)
and 15 of the 381 patients treated with placebo (3.9%)
had a thromboembolic event (P = 0.024). Five patients
in the nadroparin (0.7%) and none in the placebo group
had major bleeding (P = 0.18). The two study arms were
well balanced for demographic characteristics and can-
cer site. Patient characteristics are listed in Table 1.
Most patients were female (51.7%, 595/1150) and
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age of 64 years (range 27-84). Among the 1150 evalu-
able patients, the most common cancers were gastroin-
testinal 36.5% (420/1150), lung 24.3% (279/1150), breast
14.3% (165/1150) and ovarian 12.4% (143/1150). The
median number of chemotherapy cycles was 4 in both
placebo and treatment groups.
According to Khorana risk score patients at high risk
of TEs are equally distributed among the two arms:
8.6% and 11.1% in the nadroparin and placebo group,
respectively (Table 2).
In the nadroparin arm, chemotherapy regimens con-
taining vinca alkaloids were statistically more frequent
(11.7%, 90/769) than in the placebo arm (7.1%, 27/381),
but no other differences were found for the other che-
motherapeutic regimens.
Concomitant medications that could potentially inter-
act with blood coagulation were equally balanced in both
groups. The most common concomitant medication was
steroids (77%; 886/1150), granulocyte colony-stimulating
factor (G-CSF) (15.2%; 175/1150), nonsteroidal anti-
inflammatory drugs (NSAID) (11.7%; 135/1150) and ery-
thropoietin (7.8%; 90/1150). Data regarding
chemotherapy and concomitant medications by treat-
ment group are shown in Table 3.
Retrospective analysis results
In the absence of thromboprophylaxis (placebo group),
the highest rate of TEs was found in patients receiving
gemcitabine (8.1%; 7/86) or cisplatin (7.0%; 6/86). In
the small subset receiving etoposide or epirubicin, the
rate of TEs was 11.8% (2/17) and 8.3% (2/24), respec-
tively. In patients treated with 5-fluorouracil contain-
ing regimens, TEs occurred in 3.3% of cases (5/151)
(Table 4).
Among platinum agents (cisplatin, carboplatin and
oxaliplatin), the highest rate of TEs was found in cispla-
tin containing regimens (7.0%; 6/86), followed by carbo-
platin (5.5%; 3/55) and oxaliplatin (1.1%; 1/89) (Table 4).
The addition of gemcitabine to platinum compounds
(cisplatin or carboplatin) increased the rate of TEs to
10.2% (5/49) (Table 5). When vinca alkaloids were com-
bined with platinum compounds, the risk increased to
9.1% (1/11) (Table 5).
Antithrombotic prophylaxis with nadroparin reduced
the risk of developing a TE in comparison to placebo in
Table 1 Patient characteristics*
Nadroparin (N = 769) Placebo (N = 381)
Age (years)
Mean ± SD 62.1 ± 10.3 63.7 ± 9.2
Median (Min - Max) 64.0 (27-83) 65.0 (36-84)
Sex
Female 51.6 (397) 52.0 (198)
Male 48.4 (372) 48.0 (183)
Cancer Site
Gastrointestinal
a 35.4 (272) 38.8 (148)
Lung 25.9 (199) 21.0 (80)
Breast 14.3 (110) 14.4 (55)
Ovary 12.5 (96) 12.3 (47)
Pancreas 4.7 (36) 4.5 (17)
Head and Neck 2.5 (19) 4.5 (17)
Other 4.8 (37) 4.5 (17)
Disease Stage
Advanced 69.8 (537) 72.2 (275)
Metastatic 30.2 (233) 27.8 (106)
Chemotherapy naïve
Yes 52.7 (405) 55.9 (213)
No 47.3 (364) 44.1 (168)
Number of chemotherapy cycles
Mean ± SD 3.2 ± 1.4 3.4 ± 1.5
Median (Min - Max) 4.0 (1-7) 4.0 (1-13)
Central venous catheter
Yes 41.9 (322) 38.6 (147)
* Data are % (N) unless otherwise indicated.
aGastrointestinal (colon, rectum, stomach)
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thromboprophylaxis reduced the risk of TEs in gemcita-
bine- (RR, 95%CI: 0.32, 0.09 - 1.04), carboplatin- (RR,
95%CI: 0.15, 0.02 - 1.45) and cisplatin- (RR, 95%CI:
0.32, 0.09 - 1.12) -containing regimens (Table 4). A
relatively lower reduction in the risk of TEs was seen in
5-fluorouracil- (RR, 95%CI: 0.74, 0.24 - 2.3), vinca alka-
loids- (RR, 95%CI: 0.60, 0.06 - 6.36) and oxaliplatin-
(RR, 95%CI: 0.62, 0.04 - 9.83) -containing regimens.
Thromboprophylaxis also reduced the risk of TEs (RR,
95%CI: 0.22, 0.04 - 1.08) in patients treated with the
combination of gemcitabine and platinum compounds,
and in patients treated with vinca alkaloids and platinum
compounds (RR, 95%CI: 0.28, 0.02 - 4.15) (Table 5).
The rate of TEs in patients treated with concomitant
medications known to potentially interact with blood
coagulation has been evaluated (Table 6). In patients
administered steroids, thromboprophylaxis reduced the
risk of TEs by 40% (RR, 95%CI: 0.60, 0.06 - 6.36).
Discussion
Chemotherapy is well known to be an independent risk
factor for development of TEs in cancer patients
[23-26].
In the PROTECHT study [19], nadroparin was shown
t or e d u c et h ea b s o l u t er a t eo fc l i n i c a l l yo v e r tT E sb y
about 50% in cancer outpatients receiving chemotherapy
for metastatic or locally advanced solid tumors in
Table 3 Chemotherapy and concomitant medications by treatment group
Nadroparin (n = 769) % (n) Placebo (n = 381) % (n) P-value (two tailed)
Chemotherapy regimen containing
a:
5-Fluorouracil 37.1 (285) 39.6 (151) 0.40
Cisplatin 23.0 (177) 22.6 (86) 0.87
Gemcitabine 20.3 (156) 22.6 (86) 0.37
Oxaliplatin 18.6 (143) 23.4 (89) 0.06
Docetaxel 18.5 (142) 17.6 (67) 0.72
Carboplatin 15.5 (119) 14.4 (55) 0.64
Irinotecan 12.5 (96) 10.8 (41) 0.40
Vinca alkaloids 11.7 (90) 7.1 (27) 0.01
Capecitabine 7.9 (61) 7.9 (30) 0.97
Epirubicin 7.0 (54) 6.3 (24) 0.65
Etoposide 5.3 (41) 4.5 (17) 0.53
Cyclophosphamide 4.3 (33) 4.7 (18) 0.74
Liposomal doxorubicin 3.8 (29) 2.9 (11) 0.44
Adriamycin 3.3 (25) 5.0 (19) 0.15
Trastuzumab 3.0 (23) 2.4 (9) 0.54
Cetuximab 0.9 (7) 0.8 (3) 0.83
Bevacizumab 0.5 (4) 0.5 (2) 0.99
Concomitant Medication
b
Steroids 76.2 (586) 78.7 (300) 0.34
G-CSF 15.1 (116) 15.5 (59) 0.86
NSAID 11.2 (86) 12.9 (49) 0.41
Erythropoietin 7.4 (57) 8.7 (33) 0.46
Blood and related products 2.7 (21) 3.9 (15) 0.27
Aspirin 2.2 (17) 2.1 (8) 0.90
aThe most used antineoplastic drugs (≥ 1%) are reported in the table; the sum is not 100% of study population;
bConcomitant medications that could potentially
interact with coagulation factors; the sum is not 100% of study population
Abbreviation: G-CSF, Granulocyte colony-stimulating factor; NSAID, Nonsteroidal anti-inflammatory drugs
Table 2 Khorana risk score and Khorana risk group
evaluated among the PROTECHT patients
Nadroparin (N = 765*) Placebo (N = 378*)
Khorana Risk score
0 38.2 (292/765) 36.8 (139/378)
1 32.2 (246/765) 30.4 (115/378)
2 21 (161/765) 21.7 (82/378)
3 8 (61/765) 9.8 (37/378)
4 0.5 (4/765) 1.1 (4/378)
5 0.1 (1/765) 0.3 (1/378)
Khorana Risk group*
High risk 8.6 (66/765) 11.1 (42/378)
Intermediate risk 53.2 (407/765) 52.1 (197/378)
Low risk 38.2 (292/765) 36.8 (139/378)
Data are % (N) unless otherwise indicated. *For 4 patients in the nadroparin
group and 3 patients in the placebo group evaluation of Khorana risk score has
not be perform due to missing information for the variables(site of cancer,
platelet count, haemoglobin level, leukocyte count and body mass index).
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TECHT study thromboembolic prophylaxis could not
be reasonable for the whole ambulatory cancer patients
receiving chemotherapy. To improve the risk-benefit
ratio of thromboprophylaxis, clinicians should identify
patients at higher risk of TEs, who could have more
b e n e f i tf r o ma n t i c o a g u l a n ta d m i n i s t r a t i o n .T h ea i mo f
our retrospective analysis has been to identify in the
PROTECHT population which subgroups of patients
were at higher risk of TEs, stratified according to the
type of chemotherapy, who could have an enhanced
benefit from TEs prophylaxis.
Our results suggest that cancer outpatients receiving
chemotherapy in the absence of thromboprophylaxis
(placebo group) had a high incidence of TEs during
treatment with gemcitabine, cisplatin or carboplatin.
Etoposide and epirubicin showed also a high rate of
TEs, but in a small subgroup of patients. Among plati-
num agents, cisplatin and carboplatin showed a higher
risk of TE complications in comparison to oxaliplatin.
Combination therapy of gemcitabine with platinum-
compounds (cisplatin or carboplatin) further increased
the risk of TEs. Additionally, the combination docetaxel
with platinum compounds appeared to increase the risk
of TEs, although the sample size was too small to make
any definitive conclusions.
The thromboembolic risk of cisplatin and gemcitabine
has been previously described [14,15]. In vitro studies
have demonstrated that cisplatin activates platelets,
mononuclear cells and endothelial cells, which together
may result in a prothrombotic state [27]; however, the
exact role of gemcitabine in the activation of the coagu-
lation cascade and haemostasis remains unknown [14].
Published case series, isolated reports and observational
studies have suggested that gemcitabine, particularly if
combined with cisplatin, increases the risk of TEs
[28-30]. Cisplatin is already known as a chemotherapy
drug with a higher thromboembolic risk in comparison
to oxaliplatin [13,31]. Recently, Moore and colleagues
published a large retrospective analysis which confirmed
an unacceptable incidence of TEs in cancer patients
receiving cisplatin-based chemotherapy [32].
A tt h et i m eo ft h ee n r o l m e n ti nt h eP R O T E C H T
study, targeted therapies were not commonly used in
cancer patients. In fact, only 4.2% (48/1150) of patients
Table 4 Proportion of symptomatic TEs according to the type of chemotherapy regimen
% (n/N) (95% CI)
Thromboembolic events Nadroparin Placebo Relative risk
Overall PROTECHT population 2 (15/769) 3.9 (15/381) 0.5 (0.24-1.00)
Chemotherapy regimen containing:
5-Fluorouracil 2.5 (7/285) 3.3 (5/151) 0.74 (0.24-2.30)
Cisplatin 2.3 (4/177) 7.0 (6/86) 0.32 (0.09-1.12)
Gemcitabine 2.6 (4/156) 8.1 (7/86) 0.32 (0.09-1.05)
Oxaliplatin 0.7 (1/143) 1.1 (1/89) 0.62 (0.04-9.83)
Docetaxel 1.4 (2/142) 4.5 (3/67) 0.31 (0.05-1.84)
Carboplatin 0.8 (1/119) 5.5 (3/55) 0.15 (0.02-1.45)
Epirubicin 0.0 (0/54) 8.3 (2/24) ND
Adriamycin 0.0 (0/25) 5.3 (1/19) ND
Irinotecan 3.1 (3/96) 0.0 (0/41) ND
Vinca alkaloids 2.2 (2/90) 3.7 (1/27) 0.60 (0.06-6.36)
Capecitabine 0.0 (0/61) 3.3 (1/30) ND
Etoposide 2.4 (1/41) 11.8 (2/17) 0.21 (0.02-2.14)
Cyclophosphamide 0.0 (0/33) 5.6 (1/18) ND
Previous Chemotherapy
Naïve 2.5 (10/405) 5.2 (11/213) 0.48 (0.21-1.11)
Non-naïve 1.4 (5/364) 2.4 (4/168) 0.58 (0.16-2.12)
No TE events were observed among patients receiving trastuzumab, cetuximab, bevacizumab, liposomal doxorubicin or mitomycin. Abbreviation: ND, not
determinable.
Table 5 Proportion of symptomatic TEs in patients
receiving a platinum-based regimens (cisplatin or
carboplatin) in combination with gemcitabine, docetaxel
or vinca alkaloids
% (events/pts) (95% CI)
Platinum-based regimen* Nadroparin Placebo Relative risk
Without gemcitabine 1.5 (3/201) 4.5 (4/89) 0.33 (0.08-1.45)
With gemcitabine 2.2 (2/90) 10.2 (5/49) 0.22 (0.04-1.08)
Without docetaxel 2.2 (5/224) 6.5 (7/108) 0.34 (0.11-1.06)
With docetaxel 0.0 (0/67) 6.7 (2/30) N.D.
Without vinca alkaloids 1.6 (4/252) 6.3 (8/127) 0.25 (0.08-0.82)
With vinca alkaloids 2.6 (1/39) 9.1 (1/11) 0.28 (0.02-4.15)
*Platinum-based regimen: cisplatin or carboplatin
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mab. Nonetheless, it is worthwhile noting that the
CALGB 80303 trial [33] recently compared bevacizumab
plus gemcitabine versus gemcitabine alone in patients
with advanced pancreatic cancer. In that trial, the rates
of grade 3/4 venous thrombosis was similar in both
arms (14% and 15%, respectively) suggesting that the
role of gemcitabine in cancer-induced thrombosis could
be prevalent. Of note that currently, the efficacy of
thromboprophylaxis in patients receiving antiangiogenic
agents remains an open questions to be evaluated in
well-designed randomized trials.
According to published data [8], the rate of TEs is
more than two-fold higher in chemotherapy naïve
patients (5.2%, 11/213) compared to non-naïve patients
(2.4%, 4/168). Nadroparin prophylaxis shown a trend in
reduction for thromboembolic risk by 52% and 42% in
naïve and non-naïve patients, respectively.
The results in the global PROTECHT population have
shown that thromboprophylaxis reduced the risk of
developing TEs by 48.8% compared to placebo ([19].
Considering the subgroup of patients receiving cisplatin
or carboplatin, thromboprophylaxis reduced the risk of
thrombotic complications by 68% and 85%, respectively.
Thromboprophylaxis reduced risk of thromboembolic
complications in patients receiving gemcitabine by 68%,
further decreasing to 78% when gemcitabine was com-
bined with platinum-compounds.
Our retrospective analysis has an exploratory purpose.
Subgroup samples have not the adequate statistical
power to detect clinically meaningful differences as sta-
tistically significant and to adjust p-values for the multi-
plicity across subgroups [34]. For the same reason, a
multivariable analysis testing the interaction between
subgroups and study treatment cannot be performed
because such a statistical model would be clearly over-
parameterized. Nevertheless and despite the aforemen-
tioned limitations [35] these data could be useful for
stratifying the TE risk in ambulatory cancer population,
when planning controlled clinical studies.
In conclusion, our results suggest that patients receiv-
ing gemcitabine, cisplatin or carboplatin or their
combination are at increased risk of TEs. The clinical
benefit of thromboprophylaxis with nadroparin, in out-
patients receiving chemotherapy, could be even more
evident when gemcitabine was combined with platinum-
compounds containing regimens.
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